Investor Relations

Overview

Nabriva Therapeutics is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections. Our lead product candidate, lefamulin, is being developed as the first pleuromutilin antibiotic for intravenous (IV) and oral administration in humans. We reported positive topline efficacy and favorable tolerability results from the LEAP 1 and LEAP 2 pivotal Phase 3 trials for the treatment of community-acquired bacterial pneumonia (CABP) in adults. We believe lefamulin has the potential to be developed for additional uses and we are working to build a robust pipeline of products. Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.

Events & Presentations

Upcoming
More events are coming soon.
Prior

Wednesday August 15, 2018 10:55 AM EDT
2018 Wedbush PacGrow Healthcare Conference

Tuesday July 24, 2018 4:30 PM EDT
Nabriva Therapeutics Corporate Update Conference Call

Tuesday June 5, 2018 10:00 AM EDT
Jefferies 2018 Global Healthcare Conference

SEC Filings

Filing date Description Form Filing Group View

Amendment to a previously filed 8-K

8-K/A
Current Reports
View HTML

A preliminary proxy statement providing notification matters to be brought to a vote

PRE 14A
Proxy Filings
View HTML

An amendment to the SC 13G filing

SC 13G/A
3,4,5
View HTML

Investor Contacts

David Garrett
Vice President, Corporate Controller and Head of Investor Relations Nabriva Therapeutics plc
E-mail: david.garrett@nabriva.com